


Ask a doctor about a prescription for CONBRIZA 20 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Bazedoxifene
Contents of the pack:
CONBRIZA contains the active substance bazedoxifene, and is a medicine that belongs to a group of non-hormonal medicines called Selective Estrogen Receptor Modulators (SERMs). It is used for the treatment of osteoporosis in women after they have reached the menopause, when they have an increased risk of fractures. It works by slowing down or stopping the thinning of the bones in these women. This medicine should not be used for the treatment of osteoporosis in men.
Do not take CONBRIZA
Warnings and precautions
Talk to your doctor or pharmacist before taking CONBRIZA
These are some of the reasons why this medicine may not be suitable for you. If you find yourself in any of these situations, talk to your doctor before taking this medicine.
Using CONBRIZA with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
CONBRIZA should only be used by postmenopausal women. Pregnant or potentially pregnant women should not take it. Do not take this medicine if you are breast-feeding, as it is not known if it is excreted in breast milk.
Driving and using machines
If you feel drowsy after taking this medicine, you should avoid driving or using machines.
When taking this medicine, you may notice problems with your vision such as blurred vision. If this happens, you should avoid driving or operating machinery until your doctor tells you it is safe to do so.
CONBRIZA contains lactose
This medicine contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist. You should continue taking this medicine as long as your doctor tells you to. For the treatment of osteoporosis, this medicine should be taken daily.
If you forget to take a tablet, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take only your next scheduled dose. Do not take a double dose to make up for the missed tablet.
If you stop taking CONBRIZA
If you decide to stop taking this medicine before finishing the prescribed treatment, you should talk to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects - Stop taking CONBRIZA and see a doctor immediately
Uncommon(may affect up to 1 in 100 people):
Frequency not known(cannot be estimated from the available data):
Other side effects
Some patients have experienced the following side effects while taking CONBRIZA:
Common(may affect up to 1 in 10 people):
Frequency not known(cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month shown.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
CONBRIZA is presented as film-coated tablets, capsule-shaped and white or almost white in color, marked with “WY20”. It is packaged in PVC/Aclar blisters and is available in packs of 7, 28, 30, 84 or 90 tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder:
Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium.
Manufacturer:
Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Ireland.
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Spain
Pfizer, S.L.
Tel: +34 91 490 99 00
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CONBRIZA 20 mg FILM-COATED TABLETS – subject to medical assessment and local rules.